Case study · Bupa
How we captured behavioural evidence to de-risk Bupa's preventative-health proposition.
Demand is proved by what people do, not what they say.
The challenge
Bupa wanted to launch a preventative-health proposition built on genomics — polygenic risk scoring, medication checks, condition screening. Real build cost, real reputational exposure.
The category is littered with expensive failures: scientifically impressive tests that sold on curiosity, spiked, then stalled. One genomics proposition, behind a sophisticated and well-partnered distribution strategy, still sold fewer than a thousand consumer tests — behavioural proof that genomics without a clinical trigger doesn't convert.
The core risk was the oldest one in product — building something no one buys. The brief was to retire that risk before the build, with behavioural evidence benchmarked against the market and against itself.
Motivation does not equal action. Even proactive people who said they'd act often didn't.
What we did
Interviews and surveys shaped the hypotheses. Clicks, dwell and comprehension tested them — each feature run as its own creative, so demand attributed to the feature rather than to the Bupa brand.
What the evidence showed
Leading with the condition beat leading with the technology, and action beat education. The message we prioritised on earned around three times the click-through of the creative that led on the science behind it.
The comprehension layer then caught a false positive. For one condition the clicks looked healthy, but sustained attention ran roughly a hundred times below the rest — and the drop-off showed where in the journey people lost the thread. That told Bupa which part of the proposition to fix rather than which one to abandon. A click-only test would have shipped it.
Bupa enters build knowing which feature to lead with, for which audience, with which message — each backed by behaviour, benchmarked against the market and against rival messages.
The conclusions
What the testing settled
Which feature to lead with, for which audience, with which message — and which part of the proposition to rebuild before any spend. Ranked on behaviour rather than opinion.
What Bupa took to market
In March 2026 Bupa announced Prevention Pathways for breast cancer, cardiovascular disease and diabetes, and Bupa Medication Check for UK customers taking regular medication — expected to support more than 200,000 customers by the end of 2027.
Read Bupa's announcementThe takeaway
The cheapest way to avoid building something no one buys is to watch the market prove the pattern, design the proposition around it, then sell the feature as an ad and watch what real people do — measured against a benchmark, not a gut feel.
Contact us
Have an idea in mind? Get in touch.
No pitch, no pressure, just an honest conversation about what's possible.





Ninety Consulting Ltd (09353834)
Thanks — your message is with us. We'll be in touch shortly.